2. Anti-infection
  3. Influenza Virus
  4. Baloxavir marboxil

Baloxavir marboxil  (Synonyms: S-033188; RG 6152)

Cat. No.: HY-109025 Purity: 99.96%
COA
SDS
Handling Instructions Technical Support

Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus.

For research use only. We do not sell to patients.

CAS No. : 1985606-14-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
25 mg In-stock
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Baloxavir marboxil:

Baloxavir marboxil Related Antibodies

Top Publications Citing Use of Products

    Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2026 Dec;15(1):2601372.  [Abstract]

    Effect of Baloxavir marboxil (5-45 mg/kg; oral gavage; Twice daily for 5 days.) treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with Baloxavir marboxil or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose).

    Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Influenza Other Respir Viruses. 2025 Oct;19(10):e70176.  [Abstract]

    Five days of treatment, commencing at 1 dpi, body weight changes, and a 14-day survival rate in each group (n = 6). The survival rates in each treatment group were compared with the placebo group. he results showed that when the treatment time was extended to 5 days post-infection, both Baloxavir marboxil (BXM, 15 mg/kg; p.o.; twice daily) and combination treatments improved body weight and survival. The combination group also showed the highest survival rate.

    Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Influenza Other Respir Viruses. 2025 Oct;19(10):e70176.  [Abstract]

    Effects of the molnupiravir and Baloxavir marboxil (BXM, 15 mg/kg; p.o.; twice daily) combination treatment on the pathological changes following influenza H1N1 infection. Lung tissue harvested at 4 dpi was stained with H&E. The images on the left showed the pathological changes in each group (n = 6), with a scale bar of 2 mm. The images in the middle and right (a-h) were magnified from the corresponding squares on the left, with a scale bar of 100 μm. Histological results indicated that lung damage and inflammation in the BXM and combination groups were less severe than those in the other groups (p < 0.05).

    Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2025 Aug:240:106209.

    Inhibitory concentration 50 (IC50) expressed in nM of reference compounds (A) included in retesting experiments, (B) interval obtained through multiple determinations.
    Note: Inhibitory concentration 50 (IC50) interval of VX-787, ribavirin and oseltamivir have been obtained through multiple determinations for A/WSN/33 and A/Udorn/72. Baloxavir marboxil IC50 range for A/WSN/33 and A/Udorn/72 comes from 5 independent determinations. A/Ca/07/09 data for VX-787, Baloxavir marboxil, oseltamivir and ribavirin come from 3 independent determinations.

    Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 Feb 12:12:611958.  [Abstract]

    Antiviral activity of Baloxavir marboxil (BXA) or ATR-002 against both recombinant wild type and BXA-resistant influenza virus strains. rgA/Giessen/06/2009 (H1N1), rgA/Victoria/3/75 (H3N2). Confluent monolayer of MDCK-II cells were infected with the respective virus strains (MOI = 0.001) and incubated for 1 h. Subsequently, cells were treated by adding infection media containing either BXA (0.9 nM) or ATR-002 at the indicated concentrations. After 24 h, the virus titers were determined by focus assay.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus[1].

    In Vitro

    Baloxavir marboxil is a polymerase acidic protein (PA) endonuclease inhibitor[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Baloxavir marboxil Related Antibodies
    Clinical Trial
    Molecular Weight

    571.55

    Formula

    C27H23F2N3O7S
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(C=C1)C(OCOC(OC)=O)=C2N1N([C@H]3C4=CC=C(F)C(F)=C4CSC5=CC=CC=C35)[C@@]6([H])N(CCOC6)C2=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    DMSO : 33.33 mg/mL (58.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7496 mL 8.7481 mL 17.4963 mL
    5 mM 0.3499 mL 1.7496 mL 3.4993 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  15% Cremophor EL    85% Saline

      Solubility: 25 mg/mL (43.74 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.96%

    SDS (393 KB)

    COA (258 KB) RP-HPLC (231 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7496 mL 8.7481 mL 17.4963 mL 43.7407 mL
    5 mM 0.3499 mL 1.7496 mL 3.4993 mL 8.7481 mL
    10 mM 0.1750 mL 0.8748 mL 1.7496 mL 4.3741 mL
    15 mM 0.1166 mL 0.5832 mL 1.1664 mL 2.9160 mL
    20 mM 0.0875 mL 0.4374 mL 0.8748 mL 2.1870 mL
    25 mM 0.0700 mL 0.3499 mL 0.6999 mL 1.7496 mL
    30 mM 0.0583 mL 0.2916 mL 0.5832 mL 1.4580 mL
    40 mM 0.0437 mL 0.2187 mL 0.4374 mL 1.0935 mL
    50 mM 0.0350 mL 0.1750 mL 0.3499 mL 0.8748 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Baloxavir marboxil Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Baloxavir marboxil1985606-14-1S-033188 RG 6152S033188S 033188RG6152RG 6152RG-6152Influenza VirusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Baloxavir marboxil
    Cat. No.:
    HY-109025
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.